4,068 posters, 219 videos, 101 topics, 69 sessions, 14,365 authors, 6,128 institutions
ePostersLive by SciGen Technologies S.A. All rights reserved.
Alzheimer's Association International Conference 2026
July 12-15, 2026 | London, United Kingdom, and Online
5853
Evaluating SSRI/SNRI Use And Amyloid-related Imaging Abnormalities In Anti-amyloid Therapy In A Real World Cohort
Part of Topic
Evaluating SSRI/SNRI Use and Amyloid-Related Imaging Abnormalities in Anti-Amyloid Therapy in a Real WorldCohort
Background:
•Amyloid-related imaging abnormalities (ARIA) are a common and clinically significant adverse effect of anti-amyloid monoclonal antibody therapies (Fox et al. 2025; Sims et al. 2023; van Dyck et al. 2022)
•Selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs/SNRIs) are frequently prescribed in patients with Alzheimer’s Disease (Mo et al. 2025)
•SSRI/SNRI’s have been shown to reduce platelet aggregation (Kaye et al. 2025) and have been linked with increased risk of abnormal bleeding, particularly upper GI bleeding (Andrede et al. 2010)
• Hypothesis: SSRI or SNRI use may be associated with increased ARIA risk in individuals receiving anti-amyloid therapies
Methods:
•Retrospective chart review of 57 patients receiving lecanemab or donanemab infusions at University Hospitals (January 1, 2024- August 31, 2025)
•ARIA incidence was compared between:
Individuals on SSRI’s or SNRI’s and those not receiving these medications
•Secondary analyses: ARIA rates were compared between:
Antidepressant class (SSRI vs. SNRI)
Antidepressant dose (low vs. medium dose)
Results:
•There was no statistically significant difference in ARIA rates with vs. without antidepressant use:
SSRI/SNRI vs. ARIA → χ² p = 0.68
•Descriptively, higher ARIA rates were observed among individuals on SNRI’s (50%) compared to SSRI’s (28.6%), though the sample size was insufficient to allow meaningful statistical comparison
SSRI vs. ARIA → Fisher’s p = 0.53 (NS)
SNRI vs. ARIA → Fisher’s p = n too low
•Sample size was too low to draw conclusions about SSRI/SNRI dose (low vs. medium doses) and ARIA
ARIA vs. Low/Medium dose SSRI/SNRI → n too low
Conclusions:
•Summary: This provides an initial evaluation of the relationship between antidepressant use and ARIA risk in patients receiving anti-amyloid monoclonal antibody therapies.
•We did not identify a statistically significant association between SSRI or SNRI use or dose and ARIA rate.
•Limitations: Analyses were limited by small sample size and were retrospective.
•Future directions: Larger, prospective studies are needed to further evaluate this relationship and to account for other relevant confounders, including vascular risk factors such as blood pressure.
Comments
Email is required but is not shown publicly.
Loading comments...